We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd | NYSE:TAK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.375 | 2.86% | 13.485 | 13.49 | 13.40 | 13.40 | 433,183 | 16:13:31 |
From May 2023 to May 2024
By Michael Susin
Hutchmed (China) and Takeda Pharmaceutical said Thursday that the European Medicines Agency has accepted the marketing authorization application for fruquintinib, a treatment for previously-treated metastatic colorectal cancer, for regulatory review.
The companies said that if approved, fruquintinib will be the first treatment of its type in the European Union.
"We are thrilled to have submitted the marketing authorization application to the EMA, bringing us one step closer to potentially offering this innovative therapy to patients with advanced disease," Takeda's head of Global Medical Affairs Oncology Awny Farajallah said.
The application includes positive data from a last stage clinical trial, which demonstrated superiority of the therapy when compared with a placebo, it added.
Write to Michael Susin at michael.susin@wsj.comto Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
June 15, 2023 11:15 ET (15:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Takeda Pharmaceutical Chart |
1 Month Takeda Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
